NM_007194.4:c.757A>G
Variant summary
Our verdict is Uncertain significance. Variant got 4 ACMG points: 4P and 0B. PM2PP3_Moderate
The NM_007194.4(CHEK2):c.757A>G(p.Lys253Glu) variant causes a missense change. The variant allele was found at a frequency of 0.000000684 in 1,461,676 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_007194.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 4 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461676Hom.: 0 Cov.: 30 AF XY: 0.00000138 AC XY: 1AN XY: 727146
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Familial cancer of breast Uncertain:2
This sequence change replaces lysine, which is basic and polar, with glutamic acid, which is acidic and polar, at codon 253 of the CHEK2 protein (p.Lys253Glu). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with a personal or family history of breast and/or ovarian cancer (PMID: 27553368, 30303537). ClinVar contains an entry for this variant (Variation ID: 185057). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
- -
not provided Uncertain:1
Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Observed in individuals with a personal and family history of breast and/or ovarian cancer (PMID: 27553368, 30303537); Published functional studies suggest a neutral effect: demonstrates auto-phosphorylation and kinase activity comparable to wild type in yeast and human-cell assays (PMID: 37449874); This variant is associated with the following publications: (PMID: 22419737, 19782031, 27553368, 30303537, 37449874) -
Hereditary cancer-predisposing syndrome Uncertain:1
The p.K253E variant (also known as c.757A>G), located in coding exon 5 of the CHEK2 gene, results from an A to G substitution at nucleotide position 757. The lysine at codon 253 is replaced by glutamic acid, an amino acid with similar properties. This variant was identified in 1/80 Portuguese patients with hereditary breast and/ovarian cancer who had negative BRCA1/2 testing (Pinto P et al. Breast Cancer Res Treat, 2016 Sep;159:245-56). This variant was also identified in 1/1207 cases of French women diagnosed with breast cancer who had a sister with breast cancer and were BRCA1/2 negative and 0/1199 general population controls (Girard E et al. Int J Cancer, 2019 Apr;144:1962-1974). This variant was reported as functional in a study assessing CHEK2-complementation through quantification of KAP1 phosphorylation and CHK2 autophosphorylation in human RPE1-CHEK2-knockout cells (Stolarova L et al. Clin Cancer Res, 2023 Aug;29:3037-3050). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at